Jul 11 2012
PROLOR Biotech, Inc. (NYSE MKT: PBTH), announced that the company will present data today on its long-acting clotting factors for the treatment of hemophilia at the World Federation of Hemophilia (WFH) World Congress. PROLOR scientist Dr. Gili Hart will discuss data from preclinical studies of PROLOR's long-acting versions of Factor VIIa (Factor Vlla-CTP) and Factor lX (Factor IX-CTP) in two posters at the Congress.
Top-line results of these studies were previously reported by PROLOR. They showed that in hemophilic mouse models, PROLOR's long-acting Factor VIIa-CTP and Factor IX-CTP demonstrated superior performance on multiple measures of clotting efficacy compared to commercially available Factor VIIa and Factor IX, including survival following a bleeding challenge, generation of the pro-clotting enzyme thrombin, duration of clotting activity and number of spontaneous re-occurring bleeding episodes.
PROLOR CEO Dr. Abraham Havron commented, "The WFH World Congress is a comprehensive meeting that brings together leading researchers, physicians and patient representatives committed to improved therapies for hemophilia. We are pleased to have the opportunity to present the promising data from preclinical studies of our long-acting clotting factors to these opinion leaders as we advance them towards human clinical studies."
The posters,"F VIIa-CTP and F IX-CTP are novel long-acting coagulation factors with prolonged hemostatic activity in hemophilic animal models," Hart G, Monahan P, Seligsohn U, Zakar M, Hershkovitz O, Bar-Ilan A, Fima E, will be presented today at the WFH World Congress in Paris, France.